⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18176099 | 0.74 | — | — | |
| SCHEMBL84838 | 0.74 | — | — | |
| SCHEMBL8249419 | 0.74 | — | — | |
| SCHEMBL18116846 | 0.74 | — | — | |
| SCHEMBL10187117 | 0.74 | — | — | |
| SCHEMBL5803747 | 0.73 | — | — | |
| Hydrochloric Acid SCHEMBL28954973 | 0.72 | — | — | |
| Hydrochloric Acid SCHEMBL16465149 | 0.72 | — | — | |
| SCHEMBL1109836 | 0.70 | — | — | |
| SCHEMBL19993250 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556908-B2 | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-02-11 | — | — | US | claimed |
| US-20190106426-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2019-04-11 | — | — | US | claimed |
| US-10112950-B2 | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2018-10-30 | — | — | US | claimed |
| EP-2185549-B1 | ANTIMICROBIAL ORTHO-FLUOROPHENYL OXAZOLIDINONES FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS INC (KY) | 2018-10-03 | — | — | EP | claimed |
| US-20170369497-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2017-12-28 | — | — | US | claimed |
| US-9695180-B2 | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2017-07-04 | — | — | US | claimed |
| US-20160009720-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2016-01-14 | — | — | US | claimed |
| WO-2016007736-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2016-01-14 | — | — | WO | claimed |
| EP-1140860-B1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-09-22 | — | — | EP | claimed |
| US-6593326-B1 | Useful as anti-cancer agents; and processes for their manufacture and pharmaceutical compositions containing them are described. Apoptotic effect in a warm-blooded animal such as man. | ASTRAZENECA AB (SE) | 2003-07-15 | — | — | US | claimed |
| EP-1140860-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2001-10-10 | — | — | EP | claimed |
| WO-2000039101-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-07-06 | — | — | WO | claimed |
| EP-3107923-B1 | WATER-SOLUBLE O-CARBONYL PHOSPHORAMIDATE PRODRUGS FOR THERAPEUTIC ADMINISTRATION | SHANGHAI MICURX PHARMACEUTICAL CO LTD (CN) | 2021-11-03 | — | — | EP | disclosed |
| US-10556908-B2 | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190106426-A1 | IMIDAZOPYRAZINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2019-04-11 | — | — | US | disclosed |
| US-10112950-B2 | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2018-10-30 | — | — | US | disclosed |
| EP-1140860-B1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2004-09-22 | — | — | EP | disclosed |
| US-6593326-B1 | Useful as anti-cancer agents; and processes for their manufacture and pharmaceutical compositions containing them are described. Apoptotic effect in a warm-blooded animal such as man. | ASTRAZENECA AB (SE) | 2003-07-15 | — | — | US | disclosed |
| EP-1140860-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039101-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2000-07-06 | — | — | WO | disclosed |